![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LAMB3 |
Gene summary for LAMB3 |
![]() |
Gene information | Species | Human | Gene symbol | LAMB3 | Gene ID | 3914 |
Gene name | laminin subunit beta 3 | |
Gene Alias | AI1A | |
Cytomap | 1q32.2 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A0A0S2Z3R6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3914 | LAMB3 | CA_HPV_1 | Human | Cervix | CC | 1.34e-09 | -4.23e-01 | 0.0264 |
3914 | LAMB3 | CA_HPV_3 | Human | Cervix | CC | 4.36e-07 | 2.15e-01 | 0.0414 |
3914 | LAMB3 | HSIL_HPV_1 | Human | Cervix | HSIL_HPV | 7.98e-08 | -3.91e-01 | 0.0116 |
3914 | LAMB3 | CCI_3 | Human | Cervix | CC | 8.79e-03 | 8.53e-01 | 0.516 |
3914 | LAMB3 | Tumor | Human | Cervix | CC | 5.00e-24 | 5.94e-01 | 0.1241 |
3914 | LAMB3 | sample3 | Human | Cervix | CC | 1.21e-26 | 7.59e-01 | 0.1387 |
3914 | LAMB3 | L1 | Human | Cervix | CC | 2.17e-04 | -3.04e-01 | 0.0802 |
3914 | LAMB3 | T1 | Human | Cervix | CC | 1.04e-10 | 5.79e-01 | 0.0918 |
3914 | LAMB3 | T3 | Human | Cervix | CC | 1.47e-32 | 7.58e-01 | 0.1389 |
3914 | LAMB3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.25e-09 | 5.30e-01 | -0.1808 |
3914 | LAMB3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.23e-08 | 5.49e-01 | -0.0811 |
3914 | LAMB3 | HTA11_347_2000001011 | Human | Colorectum | AD | 9.00e-08 | 4.16e-01 | -0.1954 |
3914 | LAMB3 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.15e-02 | 8.83e-01 | -0.2602 |
3914 | LAMB3 | HTA11_83_2000001011 | Human | Colorectum | SER | 6.06e-03 | 3.48e-01 | -0.1526 |
3914 | LAMB3 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.57e-08 | 3.78e-01 | -0.1464 |
3914 | LAMB3 | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.26e-03 | 1.78e-01 | 0.0674 |
3914 | LAMB3 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.22e-02 | 6.05e-01 | 0.3487 |
3914 | LAMB3 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.83e-07 | 3.72e-01 | 0.3859 |
3914 | LAMB3 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 4.05e-04 | 4.89e-01 | 0.2585 |
3914 | LAMB3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.04e-03 | 2.58e-01 | 0.3005 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:00344469 | Cervix | CC | substrate adhesion-dependent cell spreading | 32/2311 | 108/18723 | 1.36e-06 | 4.55e-05 | 32 |
GO:00454445 | Cervix | CC | fat cell differentiation | 53/2311 | 229/18723 | 3.72e-06 | 9.75e-05 | 53 |
GO:00073695 | Cervix | CC | gastrulation | 42/2311 | 185/18723 | 5.83e-05 | 8.46e-04 | 42 |
GO:00074923 | Cervix | CC | endoderm development | 20/2311 | 77/18723 | 8.40e-04 | 7.30e-03 | 20 |
GO:0001704 | Cervix | CC | formation of primary germ layer | 27/2311 | 121/18723 | 1.49e-03 | 1.16e-02 | 27 |
GO:0050873 | Cervix | CC | brown fat cell differentiation | 13/2311 | 50/18723 | 6.42e-03 | 3.58e-02 | 13 |
GO:0030198 | Cervix | CC | extracellular matrix organization | 52/2311 | 301/18723 | 7.43e-03 | 3.98e-02 | 52 |
GO:0043062 | Cervix | CC | extracellular structure organization | 52/2311 | 302/18723 | 7.92e-03 | 4.17e-02 | 52 |
GO:0045229 | Cervix | CC | external encapsulating structure organization | 52/2311 | 304/18723 | 9.00e-03 | 4.57e-02 | 52 |
GO:00717112 | Cervix | CC | basement membrane organization | 9/2311 | 31/18723 | 1.04e-02 | 4.97e-02 | 9 |
GO:000854413 | Cervix | HSIL_HPV | epidermis development | 38/737 | 324/18723 | 1.92e-09 | 3.23e-07 | 38 |
GO:003158914 | Cervix | HSIL_HPV | cell-substrate adhesion | 30/737 | 363/18723 | 1.12e-04 | 2.34e-03 | 30 |
GO:00017041 | Cervix | HSIL_HPV | formation of primary germ layer | 13/737 | 121/18723 | 9.63e-04 | 1.20e-02 | 13 |
GO:000736911 | Cervix | HSIL_HPV | gastrulation | 16/737 | 185/18723 | 2.71e-03 | 2.58e-02 | 16 |
GO:004544413 | Cervix | HSIL_HPV | fat cell differentiation | 18/737 | 229/18723 | 4.27e-03 | 3.64e-02 | 18 |
GO:0001706 | Cervix | HSIL_HPV | endoderm formation | 7/737 | 54/18723 | 5.04e-03 | 4.12e-02 | 7 |
GO:0031589 | Colorectum | AD | cell-substrate adhesion | 116/3918 | 363/18723 | 4.68e-07 | 1.76e-05 | 116 |
GO:0034446 | Colorectum | AD | substrate adhesion-dependent cell spreading | 40/3918 | 108/18723 | 8.52e-05 | 1.32e-03 | 40 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0514514 | Cervix | CC | Toxoplasmosis | 34/1267 | 112/8465 | 2.42e-05 | 1.82e-04 | 1.08e-04 | 34 |
hsa052226 | Cervix | CC | Small cell lung cancer | 29/1267 | 92/8465 | 4.38e-05 | 3.09e-04 | 1.83e-04 | 29 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa051465 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
hsa0451014 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0514515 | Cervix | CC | Toxoplasmosis | 34/1267 | 112/8465 | 2.42e-05 | 1.82e-04 | 1.08e-04 | 34 |
hsa0522213 | Cervix | CC | Small cell lung cancer | 29/1267 | 92/8465 | 4.38e-05 | 3.09e-04 | 1.83e-04 | 29 |
hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0514612 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
hsa0514522 | Cervix | HSIL_HPV | Toxoplasmosis | 22/459 | 112/8465 | 1.07e-07 | 3.14e-06 | 2.54e-06 | 22 |
hsa0522222 | Cervix | HSIL_HPV | Small cell lung cancer | 13/459 | 92/8465 | 1.30e-03 | 9.51e-03 | 7.68e-03 | 13 |
hsa045124 | Cervix | HSIL_HPV | ECM-receptor interaction | 12/459 | 89/8465 | 2.95e-03 | 1.88e-02 | 1.52e-02 | 12 |
hsa0451023 | Cervix | HSIL_HPV | Focal adhesion | 21/459 | 203/8465 | 3.24e-03 | 2.02e-02 | 1.63e-02 | 21 |
hsa0514532 | Cervix | HSIL_HPV | Toxoplasmosis | 22/459 | 112/8465 | 1.07e-07 | 3.14e-06 | 2.54e-06 | 22 |
hsa0522232 | Cervix | HSIL_HPV | Small cell lung cancer | 13/459 | 92/8465 | 1.30e-03 | 9.51e-03 | 7.68e-03 | 13 |
hsa0451211 | Cervix | HSIL_HPV | ECM-receptor interaction | 12/459 | 89/8465 | 2.95e-03 | 1.88e-02 | 1.52e-02 | 12 |
hsa0451033 | Cervix | HSIL_HPV | Focal adhesion | 21/459 | 203/8465 | 3.24e-03 | 2.02e-02 | 1.63e-02 | 21 |
hsa04510 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
hsa045101 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
LAMB3 | ITGA1_ITGB1 | LAMB3_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMB3 | ITGA2_ITGB1 | LAMB3_ITGA2_ITGB1 | LAMININ | Breast | ADJ |
LAMB3 | CD44 | LAMB3_CD44 | LAMININ | Breast | ADJ |
LAMB3 | ITGA1_ITGB1 | LAMB3_ITGA1_ITGB1 | LAMININ | Breast | Healthy |
LAMB3 | ITGA2_ITGB1 | LAMB3_ITGA2_ITGB1 | LAMININ | Breast | Healthy |
LAMB3 | ITGA6_ITGB1 | LAMB3_ITGA6_ITGB1 | LAMININ | Breast | Healthy |
LAMB3 | ITGA7_ITGB1 | LAMB3_ITGA7_ITGB1 | LAMININ | Breast | Healthy |
LAMB3 | ITGAV_ITGB8 | LAMB3_ITGAV_ITGB8 | LAMININ | Breast | Healthy |
LAMB3 | CD44 | LAMB3_CD44 | LAMININ | Breast | Healthy |
LAMB3 | ITGA1_ITGB1 | LAMB3_ITGA1_ITGB1 | LAMININ | Breast | Precancer |
LAMB3 | ITGA2_ITGB1 | LAMB3_ITGA2_ITGB1 | LAMININ | Breast | Precancer |
LAMB3 | CD44 | LAMB3_CD44 | LAMININ | Breast | Precancer |
LAMB3 | ITGA1_ITGB1 | LAMB3_ITGA1_ITGB1 | LAMININ | Cervix | ADJ |
LAMB3 | ITGA2_ITGB1 | LAMB3_ITGA2_ITGB1 | LAMININ | Cervix | ADJ |
LAMB3 | ITGA3_ITGB1 | LAMB3_ITGA3_ITGB1 | LAMININ | Cervix | ADJ |
LAMB3 | ITGA6_ITGB1 | LAMB3_ITGA6_ITGB1 | LAMININ | Cervix | ADJ |
LAMB3 | ITGA7_ITGB1 | LAMB3_ITGA7_ITGB1 | LAMININ | Cervix | ADJ |
LAMB3 | ITGAV_ITGB8 | LAMB3_ITGAV_ITGB8 | LAMININ | Cervix | ADJ |
LAMB3 | ITGA6_ITGB4 | LAMB3_ITGA6_ITGB4 | LAMININ | Cervix | ADJ |
LAMB3 | CD44 | LAMB3_CD44 | LAMININ | Cervix | ADJ |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LAMB3 | SNV | Missense_Mutation | novel | c.2399N>T | p.Ser800Leu | p.S800L | Q13751 | protein_coding | tolerated(0.29) | benign(0.015) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
LAMB3 | SNV | Missense_Mutation | novel | c.1814N>G | p.Ala605Gly | p.A605G | Q13751 | protein_coding | tolerated(0.08) | benign(0.054) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
LAMB3 | SNV | Missense_Mutation | novel | c.2800G>A | p.Glu934Lys | p.E934K | Q13751 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
LAMB3 | SNV | Missense_Mutation | c.3096G>A | p.Met1032Ile | p.M1032I | Q13751 | protein_coding | tolerated(0.6) | benign(0.027) | TCGA-A8-A0A9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
LAMB3 | SNV | Missense_Mutation | rs202096620 | c.1328N>T | p.Pro443Leu | p.P443L | Q13751 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-B6-A40C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | cyclophosphamide | SD |
LAMB3 | SNV | Missense_Mutation | c.3428N>A | p.Arg1143His | p.R1143H | Q13751 | protein_coding | deleterious(0) | possibly_damaging(0.475) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
LAMB3 | SNV | Missense_Mutation | c.3166N>A | p.Glu1056Lys | p.E1056K | Q13751 | protein_coding | tolerated(0.27) | benign(0.001) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
LAMB3 | SNV | Missense_Mutation | rs150564174 | c.1819G>A | p.Ala607Thr | p.A607T | Q13751 | protein_coding | tolerated(0.25) | benign(0) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
LAMB3 | SNV | Missense_Mutation | c.2120G>A | p.Ser707Asn | p.S707N | Q13751 | protein_coding | tolerated(0.43) | benign(0.086) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LAMB3 | SNV | Missense_Mutation | c.1030N>A | p.Asp344Asn | p.D344N | Q13751 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-E2-A1L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3914 | LAMB3 | DRUGGABLE GENOME | CHEMBL2095222 | OCRIPLASMIN | ||
3914 | LAMB3 | DRUGGABLE GENOME | LAMB3-transduced autologous epidermal stem cells |
Page: 1 |